The first revision further clarifies the number of doses per vial for the vials that are already available, while the second revision allows for the availability of an additional multi-dose vial.
On April 1, 2021, FDA announced two revisions to the Moderna COVID-19 vaccine Emergency Use Authorization (EUA) to increase the number of vaccine doses available.
The first revision further clarifies the number of doses per vial for the vials that are already available, with the maximum number of 11 extractable doses, with a range of 10–11 doses, FDA said in a company press release. The second revision allows for the availability of an additional multi-dose vial which contains a maximum of 15 doses, with a range of 13–15 doses that can potentially be extracted.
Depending on the type of syringe and needle used to extract each dose, FDA warned that there may not be enough volume to extract more than 10 doses from the vial containing a maximum of 11 doses or more than 13 doses from the vial containing a maximum of 15 doses, according to the press release.
“Both of these revisions positively impact the supply of Moderna COVID-19 vaccine, which will help provide more vaccine doses to communities and allow shots to get into arms more quickly. Ultimately, more vaccines getting to the public in a timely manner should help bring an end to the pandemic more rapidly,” said Peter Marks, MD, PhD, director of FDA’s Center for Biologics Evaluation and Research, in the press release.
Source: FDA
Regeneron Treatment for Multiple Myeloma Gets Conditional Marketing Approval from EC
April 29th 2025The indication is specific to patients who have received at least three prior therapies, including a proteasome inhibitor, immunomodulatory agent, and anti-CD38 monoclonal antibody, and have demonstrated disease progression on the last therapy.
MHRA Approves GSK Therapy Combinations for Multiple Myeloma
April 21st 2025Belantamab mafodotin is approved in combination with bortezomib plus dexamethasone in patients who have had at least one prior therapy, and in combination with pomalidomide plus dexamethasone for those who have had a prior therapy including lenalidomide.